2 terminated, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Withdrawn 1 |
Follow GED0301: new trials by email Literature Review of GED0301 trials Research Report on GED0301
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease GED-0301, Placebo - Crohn Disease | Phase 3 | Withdrawn | Celgene | 2017-12-01 | 2017-11-14 | |
| A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease GED-0301, Placebo - Crohn's Disease | Phase 3 | Terminated | Celgene | 310 | 2016-07-25 | 2019-01-29 |
| Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease GED-0301, Placebo - Crohn Disease | Phase 3 | Terminated | Celgene | 701 | 2015-12-08 | 2019-08-28 |
Crohn Disease (3) · Irritable Bowel Syndrome (1)
Celgene (3)
Australia (3) · Austria (3) · Belgium (3) · Canada (3) · Croatia (3) · Czechia (3) · Denmark (3) · France (3) · Germany (3) · Greece (3) · Hungary (3) · Israel (3) · Italy (3) · Latvia (3) · Netherlands (3)
Guillermo Rossiter, MD (2) · Denesh Chitkara, MD (1)